ArticleCell death discovery2025
Retinal degeneration protein 3 mutants are associated with cell-cycle arrest and apoptosis.
Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Retinal degeneration protein 3 (RD3) plays a crucial role in controlling guanylate cyclase activity in photoreceptor rod and cone cells, and mediates trafficking processes within photoreceptor cells. Loss of RD3 function correlates with severe forms of retinal dystrophy and the development of aggressive neuroblastoma cancer. In the present study, we analyzed RD3 expression in glioblastoma in comparison to non-tumor tissue using public databases and qRT-PCR. We found that RD3 is downregulated in glioblastoma compared to non-tumor tissues. To better understand the cellular function of RD3 in the context of tumor development, we performed first functional cell culture studies to clarify a possible involvement of RD3 in cell survival and the cell cycle. Interestingly, RD3 overexpression significantly decreased cell viability, which subsequently led to cell-cycle arrest at the G2/M phase and induced cell apoptosis. Conversely, single-point mutations in RD3 at the exposed protein surface involved in RD3-target interaction diminished the impact of RD3. Therefore, a controlled RD3 expression level seems to be important for a balance of cell death and cell survival rate. These new functional mechanisms of RD3 expression could help in understanding tumor development and growth.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.